BRAFV600E melanomas, which have low expression of EGFR, are treatable with RAF inhibitors (e.g., vemurafenib); however, BRAFV600E colorectal cancers adapt to RAF inhibitors through compensatory activation of the EGFR and MAPK signaling pathways [175,176]. This evidence concerns the gene EGFR and melanoma.